* Note: Prices are in Million (M) USD.
Description:
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $28 M
Debt : $18 M
EBITDA : $-47 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Medical Devices
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-12 M
Average Revenue: $21 M
Revenue Converted To Free Cash Flow (%): -55%
Avg Free Cash Flow Growth Per Year (Last 5 Years): -32.44%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $39 M
Revenue 4 Years Ago (2020-12-31): $26 M
Last 5 Years Average Revenue Growth: 10%
Since Revenue Growth is between 5 - 10, 2 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $105 M
Share Count 5 Years Ago (2020-12-31): $69 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -42%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $1
52-Week Low: $2
Threshold Price (15% Above 52-Week Low): $2
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $217 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Value-Trade has assigned 14 points to above MaxCyte Inc (MXCT) stock.
Fair Value PE 12, Industry Based PE 18, Growth Based PE 9. Based on these 3 values, average assigned is 13.00.
The fair value of MaxCyte Inc (MXCT) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
